Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency
Drug Saf
.
2023 Mar;46(3):319-321.
doi: 10.1007/s40264-023-01275-7.
Epub 2023 Feb 14.
Authors
Karl Mikael Kälkner
1
,
Anders Sundström
2
,
Marja-Leena Nurminen
2
,
Maria Larsson
2
,
Rickard Ljung
2
,
Veronica Arthurson
2
Affiliations
1
Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden. karl-mikael.kalkner@lakemedelsverket.se.
2
Division of Use and Information, Swedish Medical Products Agency, PO Box 26, 751 03, Uppsala, Sweden.
PMID:
36786959
PMCID:
PMC9926420
DOI:
10.1007/s40264-023-01275-7
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Product Surveillance, Postmarketing
SARS-CoV-2
Sweden / epidemiology
Vaccination
Vaccines*
Substances
COVID-19 Vaccines
Vaccines